← The Wire
FATENasdaq
FATE THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · CIK 1434316
Develops off-the-shelf cellular immunotherapies from engineered stem cells for broad patient access
red 8-K · 90d
$240M
Market cap
$2.42
Last close
+15.2%
1D
+12.6%
5D
5.9M
Volume
Price · last 39 sessions+34.4%
May 4L $1.73 · H $2.84Jun 29
249
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GFeb 12, 2024SC 13GFATE THERAPEUTICS INCJan 25, 2024SC 13GSC 13GMar 22, 2023SC 13GSEC SCHEDULE 13GFeb 13, 2023SC 13GSC 13GFeb 3, 2023SC 13GSC 13GSep 10, 2021SC 13GSCHEDULE 13GFeb 10, 2021SC 13GSC 13GJan 31, 2020SC 13GSC 13GFeb 8, 2019SC 13GSC 13GFeb 14, 2017SC 13GTHE SCHEDULE 13GDec 1, 2016SC 13GSC 13GSep 9, 2016SC 13GSC 13GFeb 16, 2016SC 13GSC 13GFeb 17, 2015SC 13GDISCLOSURE DOCUMENTFeb 14, 2014SC 13GSC 13GNov 12, 2013SC 13GSC 13GOct 11, 2013
Insider Activity
In the 90 days to Jan 9, 2026: 2 sold $17K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 9, 2026 | Tahl CindySee Remarks | Sell | 10,589 | $1.06 | $11K |
| Jan 9, 2026 | Valamehr BahramPresident and CEO | Sell | 5,190 | $1.07 | $6K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance